Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - LU2458332611 - Common Stock

8.07 USD
+0.02 (+0.25%)
Last: 8/29/2025, 8:06:12 PM
8.07 USD
0 (0%)
After Hours: 8/29/2025, 8:06:12 PM
Fundamental Rating

4

Taking everything into account, ALVO scores 4 out of 10 in our fundamental rating. ALVO was compared to 547 industry peers in the Biotechnology industry. While ALVO is still in line with the averages on profitability rating, there are concerns on its financial health. ALVO is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ALVO has reported negative net income.
ALVO had a negative operating cash flow in the past year.
ALVO had negative earnings in each of the past 5 years.
ALVO had a negative operating cash flow in each of the past 5 years.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

With an excellent Return On Assets value of 7.75%, ALVO belongs to the best of the industry, outperforming 92.32% of the companies in the same industry.
With an excellent Return On Invested Capital value of 10.37%, ALVO belongs to the best of the industry, outperforming 94.33% of the companies in the same industry.
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROIC 10.37%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

ALVO has a Profit Margin of 16.42%. This is amongst the best in the industry. ALVO outperforms 93.97% of its industry peers.
ALVO has a better Operating Margin (21.88%) than 95.43% of its industry peers.
ALVO has a Gross Margin of 60.74%. This is in the better half of the industry: ALVO outperforms 78.43% of its industry peers.
Industry RankSector Rank
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALVO is still creating some value.
ALVO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ALVO has been reduced compared to a year ago.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.63, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
ALVO's Altman-Z score of -0.63 is fine compared to the rest of the industry. ALVO outperforms 60.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.63
ROIC/WACC1.51
WACC6.88%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 1.73 indicates that ALVO should not have too much problems paying its short term obligations.
ALVO's Current ratio of 1.73 is on the low side compared to the rest of the industry. ALVO is outperformed by 78.43% of its industry peers.
A Quick Ratio of 1.19 indicates that ALVO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.19, ALVO is doing worse than 83.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.19
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.39% over the past year.
ALVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 426.84%.
ALVO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.86% yearly.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, ALVO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.57% on average per year.
ALVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.74% yearly.
EPS Next Y96.48%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue Next Year41.5%
Revenue Next 2Y43.82%
Revenue Next 3Y41.74%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 16.31 indicates a correct valuation of ALVO.
94.15% of the companies in the same industry are more expensive than ALVO, based on the Price/Forward Earnings ratio.
ALVO is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.72, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 16.31
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALVO is valued cheaply inside the industry as 93.42% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.96
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

ALVO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVO's earnings are expected to grow with 46.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.27%
EPS Next 3Y46.57%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (8/29/2025, 8:06:12 PM)

After market: 8.07 0 (0%)

8.07

+0.02 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners6%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap2.51B
Analysts78
Price Target17.85 (121.19%)
Short Float %0.94%
Short Ratio3.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)225.45%
Min EPS beat(2)38.96%
Max EPS beat(2)411.94%
EPS beat(4)4
Avg EPS beat(4)2391.55%
Min EPS beat(4)38.96%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)33.69%
Min Revenue beat(2)30.36%
Max Revenue beat(2)37.03%
Revenue beat(4)3
Avg Revenue beat(4)19.69%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)37.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.23%
PT rev (3m)-2.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-131.03%
EPS NY rev (3m)-180%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-2.1%
Revenue NY rev (3m)9.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.31
P/S 4.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 22.96
EPS(TTM)-0.87
EYN/A
EPS(NY)0.49
Fwd EY6.13%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.89
BVpS-0.97
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROCE 13.13%
ROIC 10.37%
ROICexc 10.8%
ROICexgc 11.19%
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 7.35
Cap/Depr 234.04%
Cap/Sales 12.89%
Interest Coverage 2.32
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.19
Altman-Z -0.63
F-Score6
WACC6.88%
ROIC/WACC1.51
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y96.48%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year41.5%
Revenue Next 2Y43.82%
Revenue Next 3Y41.74%
Revenue Next 5YN/A
EBIT growth 1Y141.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year191.3%
EBIT Next 3Y86.48%
EBIT Next 5YN/A
FCF growth 1Y45.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.75%
OCF growth 3YN/A
OCF growth 5YN/A